Currently, several studies are registered in the clinicaltrials.gov platform aiming to investigate the effects of ACEi/ARBs replacement or withdrawn on patients with COVID-19 (Table 1), the impact of ACEi/ARBs initiation in patients without hypertension on the risk of COVID-19 infection and severity (Table 2) and whether modulation of RAS by other agents with antihypertensive actions [AT1R biased agonist, Ang-(1-7) analogs, DPP4 inhibitors or recombinant ACE2] can impact COVID-19 outcomes (Table 3). Here, DPP4 is linked to hypertensive disorder.